Cas:2425-95-8 4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline manufacturer & supplier

Chemical Name:4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline

CAS.NO:2425-95-8

Synonyms:2-(n-aminophenyl)-5-(n-aminophenyl)-1,3,4-oxadiazole;2,5-BIS(4-AMINOPHENYL)-1,3,4-OXADIAZOLE;2,5-bis(4-aminophenylene)-1,3,4-oxadiazole;EINECS 219-373-8;2,5-bis(p-aminophenyl)-1,3,4-oxadiazole;4,4′-(1,3,4-Oxadiazole-2,5-diyl)dianiline;2,5-Bis-(4-aminophenyl)-1,3,4-oxadiazole;2,5-bis(4-aminobenzoyl)-1,3,4-oxadiazole;MFCD00042667

Molecular Formula:C₁₄H₁₂N₄O

Molecular Weight:252.27100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:250-254 °C(lit.)

Boiling point:508.1ºC at 760mmHg

Density:1.301g/cm3

Index of Refraction:1.669

PSA:90.96000

Exact Mass:252.10100

LogP:3.73040

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 2-(n-aminophenyl)-5-(n-aminophenyl)-1,3,4-oxadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00042667 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4′-(1,3,4-Oxadiazole-2,5-diyl)dianiline Use and application,MFCD00042667 technical grade,usp/ep/jp grade.

Related News: As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. 4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline manufacturer Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline supplier As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. 4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline vendor In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant. 4-[5-(4-aminophenyl)-1,3,4-oxadiazol-2-yl]aniline factory Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.